PMIScience

Clinical research is a cornerstone of our smoke-free product assessment. At Philip Morris International, we conduct clinical studies to evaluate the potential of our smoke-free products to reduce exposure to harmful chemicals and reduce the risk of harm as compared with…

At Philip Morris International, we set ourselves the highest standards in our science and research practices. This is why we follow pharmaceutical industry standards to scientifically substantiate our smoke-free products. This includes internationally recognized guidelines for…

Substances used to measure the effect of exposure to a harmful chemical on the human body are known as biomarkers of potential harm (BoPH). Our clinical studies on biomarkers demonstrate that adult smokers who switch completely to our leading heated tobacco product have…

Why do we share our research results openly? Sharing our research through peer-reviewed publications, conference presentations, and on PMIScience.com builds transparency and trust in our science and fosters informed dialogue on the potential benefits of smoke-free…

Postmarket safety surveillance is the practice of monitoring the safety of a product after it has been released on the market. Why is it important? It helps us track, analyze, and communicate information about health-related events that are not necessarily caused by product use…

What do the safety monitoring data show about our leading heated tobacco product? Between 2014 and the end of 2024, the percentage of serious adverse events reported has remained stable at an average of 2.28% of all recorded events, even as the number of users has increased…

Postmarked safety surveillance ensures the timely detection and handling of safety signals, helps strengthen consumer safety measures, supports responsible innovation, and contributes to product improvement. Explore Philip Morris International’s safety surveillance program in…

Our latest facts and figures highlight PMI’s progress toward a smoke-free future. Since 2008, we have invested USD 14 billion in the development, testing, manufacturing, and responsible commercialization of smoke-free products. This investment is delivering results: As of…

Harm reduction is a pragmatic, science-based approach to public health that aims to minimize the negative consequences of risky behaviors without necessarily eliminating the behaviors themselves. Think about seatbelts or bicycle helmets. These are examples of the many harm…

In 2020, Greece became the first EU country to permit the use of scientifically substantiated claims related to the reduced health risks of smoke-free alternatives. This decision aligned with Greece’s National Action Plan Against Smoking, a regulatory approach that supports…

What role does nicotine play in tobacco harm reduction? Nicotine is addictive and not risk free, but it is not the primary cause of smoking-related diseases such as cancer, lung disease, and heart disease. These diseases are primarily caused by the high numbers and levels of…

Are doctors always right about nicotine? A 2022 survey shows that nearly 80% of physicians worldwide mistakenly believe that nicotine causes lung cancer. The survey also revealed that more than 80% of U.S. physicians believe nicotine causes cardiovascular disease (CVD) and…

How likely are adult smokers who don’t quit to switch to Philip Morris International (PMI) smoke-free products? Exactly who uses PMI smoke-free products? Why is it important to inform adult smokers about the benefits and risks of switching to smoke-free alternatives? The…

How does Philip Morris International (PMI) measure consumer perception and behavior for its smoke-free products? By developing innovative tools and collaborating with other organizations to standardize perception and behavior research. Read about how PMI collaborates and uses…

Risk perception matters—our studies show that when adult smokers understand the relative health risks of cigarettes versus smoke-free products, they're more likely to switch. In an interview in the latest issue of our Scientific Update magazine, Steve Roulet, PMI’s Global Head…

All scientific research deserves a platform. When science leads, society benefits. See how PMI’s science can contribute to a smoke-free future ➡️ spr.ly/6011ff26b #OpenScience #PublicHealth #ScientificResearch #ScientificEvidence

In the latest issue of our Scientific Update, Steve Roulet, PMI’s Global Head of Regulatory Insights, discusses our perception and behavior studies program and its contribution to advancing tobacco harm reduction efforts. Read more here ➡️ spr.ly/6015fIWpf…

When our leading heated tobacco product was launched in 2014, Philip Morris International was the first tobacco company to establish a safety surveillance system. Present in more than 80 countries, the system covers the collection of cases from multiple sources, case processing…

“Disparities in nicotine regulation are creating a global divide with profound health and economic impacts.” - Jacek Olczak, Chief Executive Officer Read an eye-opening article exploring how countries like New Zealand have implemented a risk-proportionate approach to the…

By following the internationally recognized guidelines for Good Clinical Practice (GCP), we document the clinical research process to provide a reliable record of events. Moreover, this documentation follows the ALCOA principles (Attributable, Legible, Contemporaneous, Original,…